Anbio Biotechnology (NNNN)

Every figure this model derived for NNNN, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
cash 11,901,231 CashAndCashEquivalentsAtCarryingValue 2025-12-31
current assets 30,242,859 AssetsCurrent 2025-12-31
current liabilities 87,836 LiabilitiesCurrent 2025-12-31
equity 30,155,023 StockholdersEquity 2025-12-31
ocf -6,739,075 NetCashProvidedByUsedInOperatingActivities 2025-12-31
revenue 8,646,844 RevenueFromContractWithCustomerIncludingAssessedTax 2025-12-31

The ratios

The figures themselves rather than their scores — what somebody looking up NNNN on one particular measure came for.

RatioValue
cash operating margin66.7
current ratio344.31
current ratio reported344.31
dilution pct3.27
ebit cagr-17.29
ebit yoy189.06
fcf margin-77.94
operating margin66.7
owner earnings margin-77.94
revenue growth5.64
revenue growth per share2.3
roic24.96
rule of 4072.34
sbc pct revenue0.0

What to be careful about

What this model itself distrusts about NNNN's figures. Written by the derivation as it ran, not added afterwards.